Table 3 Clinicopathological and genetic characteristics of Omani CRC cases.
| Omani | |||||
|---|---|---|---|---|---|
| All | non-MSI-H | MSI-H | Odds Ratio | P | |
| Number of patients | 61 | 53 (87)a | 8 (13)a | ||
| Mean Age |
52.7+13.6 - |
53.1+12.8 - |
51.5+19.2 - | 0.76 | |
| Gender | 0.37 | ||||
| Female | 24 (39) | 22 (42) | 2 (25) | 1 | |
| Male | 37 (61) | 31(58) | 6 (75) | 2.12(0.39–11.55) | |
| Site | 61 | 0.75 | |||
| Distal | 51 (84) | 44(83) | 7(87) | 1 | |
| Proximal | 10 (16) | 9(17) | 1(13) | 1.43(0.16–13.11) | |
| Mucin Production | 61 | 0.44 | |||
| None | 47 (77) | 42(78) | 5 (63) | 1 | |
| < 50% | 14(23) | 11 (20) | 3(37) | 2.3(0.47–11.10) | |
| > 50% | 0 | 0 | 0 | NA | |
| Differentiation | 60 | 0.44 | |||
| Well | 7 (12) | 7 (14) | 0 | NA | |
| Moderate | 49(82) | 43 (81) | 6(86) | 1 | |
| Poor | 4 (6) | 3 (6) | 1 (14) | 2.39(0.21–26.84) | |
| Stage | 61 | 0.28 | |||
| Stage 1 | 1 (2) | 1 (2) | 0 | NA | |
| Stage 2 | 20 (33) | 15 (28) | 5 (62) | 1 | |
| Stage 3 | 31 (50) | 29 (55) | 2 (25) | 0.21(0.02–1.50) | |
| Stage 4 | 9 (15) | 8 (15) | 1 (13) | 0.38(0.01–4.41) | |
| BRAF | 59 | 0.62 | |||
| Wild type | 48 (81) | 42 (82) | 6 (75) | 1 | |
| V600E | 11 (19) | 9 (18) | 2 (25) | 1.56(0.27–9.0) | |
| hMLH1 methylation (MSP) | 49 | 0.47 | |||
| Unmethylation | 8 (16) | 6(14.6) | 2 (25) | 1 | |
| Methylation | 41 (84) | 35 (85.4) | 6 (75) | 0.51(0.08–3.17) | |
| p16 methylation (MSP) | 44 | 0.09 | |||
| Unmethylation | 27(62) | 20 (56) | 7 (88) | 1 | |
| Methylation | 17 (38) | 16 (44) | 1 (12) | 0.18(0.02–1.61) | |
| hMLH1 expression by IHC | 61 | 0.68 | |||
| Normal | 42 (69) | 37(70) | 5 (62) | 1 | |
| Negative | 19 (32) | 16 (30) | 3(38) | 1.39(0.29–6.67) | |
| hMSH2 expression by IHC | 61 | 0.63 | |||
| Normal | 56 (92) | 49 (92) | 7(87) | 1 | |
| Negative | 5 (8) | 4 (8) | 1(13) | 1.75(0.17–16.67) |
